背景:医护人员(HCWs)一直在COVID-19大流行的前线工作,具有很高的病毒暴露风险,感染,和传输。标准的COVID-19检测不足以保护HCWs免受这些风险并防止疾病传播。使用可穿戴传感器持续监测生理数据,自我监测症状,无症状的COVID-19检测可能有助于在HCWs中早期发现COVID-19,并可能有助于减少HCWs之间的进一步传播,病人,和家庭。
目的:通过使用可穿戴传感器,基于智能手机的症状记录,和生物标本,该项目旨在帮助医务人员自我监测COVID-19。
方法:我们进行了前瞻性,在单一机构进行HCWs的纵向研究。研究时间为1年,其中指示参与者连续使用两个可穿戴传感器(FitbitCharge3智能手表和TempTraq温度贴片)长达30天。参与者同意提供生物标本(即,鼻拭子,唾液拭子,和血液)从研究进入后长达1年。使用名为Roadmap2.0的智能手机应用程序,参与者输入了每日情绪评分,每天提交COVID-19症状,并在研究进入时和30天后完成人口统计学和健康相关的生活质量调查。在30天期限结束时也进行了半结构化的定性访谈,在完成日常情绪和症状报告以及连续可穿戴传感器使用之后。
结果:在2020年4月28日至12月7日期间,共有226名HCWs入组。最后一位参与者于2021年1月16日完成了为期30天的研究程序。数据收集将持续到2023年1月,数据分析正在进行中。
结论:使用可穿戴传感器,基于智能手机的症状记录和调查完成,和生物样本收集,这项研究可能提供单一机构的HCWs中COVID-19感染率的数据.该研究还将评估利用可穿戴传感器和HCW人群症状自我监测的可行性。
背景:ClinicalTrials.govNCT04756869;https://clinicaltrials.gov/ct2/show/NCT04756869。
■DERR1-10.2196/29562。
BACKGROUND: Health care workers (HCWs) have been working on the front lines of the COVID-19 pandemic with high risks of viral exposure, infection, and transmission. Standard COVID-19 testing is insufficient to protect HCWs from these risks and prevent the spread of disease. Continuous monitoring of physiological data with wearable sensors, self-monitoring of symptoms, and asymptomatic COVID-19 testing may aid in the early detection of COVID-19 in HCWs and may help reduce further transmission among HCWs, patients, and families.
OBJECTIVE: By using wearable sensors, smartphone-based symptom logging, and biospecimens, this project aims to assist HCWs in self-monitoring COVID-19.
METHODS: We conducted a prospective, longitudinal study of HCWs at a single institution. The study duration was 1 year, wherein participants were instructed on the continuous use of two wearable sensors (Fitbit Charge 3 smartwatch and TempTraq temperature patches) for up to 30 days. Participants consented to provide biospecimens (ie, nasal swabs, saliva swabs, and blood) for up to 1 year from study entry. Using a smartphone app called Roadmap 2.0, participants entered a daily mood score, submitted daily COVID-19 symptoms, and completed demographic and health-related quality of life surveys at study entry and 30 days later. Semistructured qualitative interviews were also conducted at the end of the 30-day period, following completion of daily mood and symptoms reporting as well as continuous wearable sensor use.
RESULTS: A total of 226 HCWs were enrolled between April 28 and December 7, 2020. The last participant completed the 30-day study procedures on January 16, 2021. Data collection will continue through January 2023, and data analyses are ongoing.
CONCLUSIONS: Using wearable sensors, smartphone-based symptom logging and survey completion, and biospecimen collections, this study will potentially provide data on the prevalence of COVID-19 infection among HCWs at a single institution. The study will also assess the feasibility of leveraging wearable sensors and self-monitoring of symptoms in an HCW population.
BACKGROUND: ClinicalTrials.gov NCT04756869; https://clinicaltrials.gov/ct2/show/NCT04756869.
UNASSIGNED: DERR1-10.2196/29562.